S
Soo-Jung Kim
Researcher at University of Pennsylvania
Publications - 6
Citations - 190
Soo-Jung Kim is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Progressive supranuclear palsy & Tauopathy. The author has an hindex of 5, co-authored 5 publications receiving 102 citations. Previous affiliations of Soo-Jung Kim include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Transmission of tauopathy strains is independent of their isoform composition
Zhuohao He,Zhuohao He,Jennifer D. McBride,Hong Xu,Lakshmi Changolkar,Soo-Jung Kim,Bin Zhang,Sneha Narasimhan,Garrett S. Gibbons,Jing L. Guo,Michael Kozak,Gerard D. Schellenberg,John Q. Trojanowski,Virginia M.-Y. Lee +13 more
TL;DR: A new transgenic mouse line is generated expressing 6 human tau isoforms with equal 3R and 4R ratios, recapitulate distinct human t Tau strains in mouse brains with similar isoform compositions and cell type specificities, and further show the strain transmission pattern is independent of its isoform composition.
Journal ArticleDOI
Characterization of tau binding by gosuranemab.
Richelle Sopko,Olga Golonzhka,Joseph Arndt,Chao Quan,Julie Czerkowicz,Andrew Cameron,Benjamin Smith,Yogapriya Murugesan,Garrett S. Gibbons,Soo-Jung Kim,John Q. Trojanowski,Virginia M.-Y. Lee,Kurt R. Brunden,Danielle Graham,Paul H. Weinreb,Heike Hering +15 more
TL;DR: A detailed biochemical and biophysical characterization of the tau-binding properties of gosuranemab, a humanized monoclonal antibody directed against N-terminal tau that is currently being investigated as a treatment for AD is reported.
Journal ArticleDOI
Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
Garrett S. Gibbons,Soo-Jung Kim,John L. Robinson,Lakshmi Changolkar,David J. Irwin,David J. Irwin,Leslie M. Shaw,Virginia M.-Y. Lee,John Q. Trojanowski +8 more
TL;DR: The use of GT-38 is validated to selectively detect AD-tau pathology in the context of FTLD- tau and provides a novel tool to investigate associations of clinical phenotypes amongst co-morbid tauopathies.
Journal ArticleDOI
In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics.
Hong Xu,Mia O’Reilly,Garrett S. Gibbons,Lakshmi Changolkar,Jennifer D. McBride,Dawn M. Riddle,Bin Zhang,Anna Stieber,Jeffrey J. Nirschl,Soo-Jung Kim,Kevt’her Hoxha,Kurt R. Brunden,Gerard D. Schellenberg,John Q. Trojanowski,Virginia M.-Y. Lee +14 more
TL;DR: In this article, a modified seeding protocol was used to template the recruitment of recombinant 2N4R (T40) tau protein in vitro, and the efficacy of the amplification reactions and the pathogenic fidelity of the amplified material to the original tau seeds using recently developed sporadic tau spreading models.
Journal ArticleDOI
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease
Garrett S. Gibbons,Soo-Jung Kim,Qihui Wu,Dawn M. Riddle,Susan Leight,Lakshmi Changolkar,Hong Xu,Emily S. Meymand,Mia O’Reilly,Bin Zhang,Kurt R. Brunden,John Q. Trojanowski,Virginia M.-Y. Lee +12 more
TL;DR: Findings demonstrate that conformation-selective tau mAbs, DMR7 and SKT82, inhibit tau pathology in primary neurons by preventing the uptake of tau seeds and reduce t Tau pathology in vivo, providing potential novel therapeutic candidates for the treatment of AD.